| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/12/2003 | WO2003047626A1 Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| 06/12/2003 | WO2003047616A1 Migration of hematopoietic stem cells and progenitor cells to th e liver |
| 06/12/2003 | WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism |
| 06/12/2003 | WO2003047608A1 A novel herbal chemical composition for the treatment of cancer |
| 06/12/2003 | WO2003047606A2 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |
| 06/12/2003 | WO2003047598A1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists |
| 06/12/2003 | WO2003047590A1 Antibiotic formulation and a method of making this formulation |
| 06/12/2003 | WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors |
| 06/12/2003 | WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| 06/12/2003 | WO2003047579A1 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| 06/12/2003 | WO2003047578A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist |
| 06/12/2003 | WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
| 06/12/2003 | WO2003047576A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 06/12/2003 | WO2003047570A1 Benzazole derivatives for the treatment of scleroderma |
| 06/12/2003 | WO2003047568A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
| 06/12/2003 | WO2003047560A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| 06/12/2003 | WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof |
| 06/12/2003 | WO2003047523A2 Raf-mek-erk pathway inhibitors to treat cancer |
| 06/12/2003 | WO2003047522A2 Composition and method for decreasing upper respiratory airway resistance |
| 06/12/2003 | WO2003047521A2 Composition and method for treatment of otitis media |
| 06/12/2003 | WO2003047519A2 'compressed annular tablet with molded triturate tablet for oral and intraoral' |
| 06/12/2003 | WO2003047513A2 Method for treating ocular hypertension |
| 06/12/2003 | WO2003047512A2 Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| 06/12/2003 | WO2003047504A2 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 06/12/2003 | WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 06/12/2003 | WO2003047420A2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| 06/12/2003 | WO2003047353A1 Probiotic formulation and method for reduction of pathogenic bacteria |
| 06/12/2003 | WO2003027282A9 Adamts-15, -16, -17, -18 and -19 |
| 06/12/2003 | WO2003017928A3 Method for treating bronchial constriction and bronchospam |
| 06/12/2003 | WO2003005962A3 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 06/12/2003 | WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions |
| 06/12/2003 | WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/12/2003 | WO2002057465A3 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 06/12/2003 | WO2002009683A9 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 06/12/2003 | WO2001085096A9 Mast cell regulation |
| 06/12/2003 | WO2001073133A9 Compositions and methods for identifying and targeting cancer cells |
| 06/12/2003 | WO2001054677A9 Ace inhibitor-vasopressin antagonist combinations |
| 06/12/2003 | US20030109699 Biopolymers; gene therapy, medical diagnosis |
| 06/12/2003 | US20030109675 Therapy for infections; enzyme inhibitors |
| 06/12/2003 | US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide |
| 06/12/2003 | US20030109582 Methods and compositions for stimulating secretions from paneth cells |
| 06/12/2003 | US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol. |
| 06/12/2003 | US20030109558 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 06/12/2003 | US20030109546 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| 06/12/2003 | US20030109544 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| 06/12/2003 | US20030109540 Pharmaceutical dosage forms comprising descarboethoxyloratadine |
| 06/12/2003 | US20030109536 Treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. treatment of anxiety, depression, a sleep disorder, attention deficit disorder, or Alzheimer's dementia, |
| 06/12/2003 | US20030109534 Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis |
| 06/12/2003 | US20030109529 Treating humans and animals infected by Apicomplexan parasites. More specifically, the present invention relates to treating an Apicomplexan infection by administering s-triazines, such as atrazine, to an infected human or animal. |
| 06/12/2003 | US20030109520 Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| 06/12/2003 | US20030109511 Novel anti-inflammatory androstane derivative compositions |
| 06/12/2003 | US20030109510 Pharmaceutical formulations comprising a combination of (R,R)-formoterol and budesonide and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases |
| 06/12/2003 | US20030109509 Methods for treating dry eye |
| 06/12/2003 | US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in |
| 06/12/2003 | US20030109503 Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics |
| 06/12/2003 | US20030109500 Compositions and methods for use in targeting vascular destruction |
| 06/12/2003 | US20030109492 Methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with beta |
| 06/12/2003 | US20030109488 Methods for treating dry eye |
| 06/12/2003 | US20030109486 Methods and therapeutic compositions for utilization of adenosine 5'-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) |
| 06/12/2003 | US20030109485 Pharmaceutical combination |
| 06/12/2003 | US20030109481 Tumour-cell specific gene expression and its use in cancer therapy |
| 06/12/2003 | US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and |
| 06/12/2003 | US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications. |
| 06/12/2003 | US20030109448 Enhancing cellular uptake and redistributing gene regulating polyamides from the extranuclear areas in eukaryotic cells to the nucleus thereof. The method consists of administering to the eukaryotic cells a molecular trafficking compound |
| 06/12/2003 | US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally |
| 06/12/2003 | US20030109435 Methods of inhibiting amyloid toxicity |
| 06/12/2003 | US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 06/12/2003 | US20030109419 Detection and tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical |
| 06/12/2003 | US20030109417 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle |
| 06/12/2003 | US20030109004 Culture product; cell transformation; genetic engineering using promoter |
| 06/12/2003 | US20030108998 Aggrecan degrading metallo proteases |
| 06/12/2003 | US20030108966 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| 06/12/2003 | US20030108961 Methods and compositions for diagnosing breast cancer |
| 06/12/2003 | US20030108937 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 |
| 06/12/2003 | US20030108928 MID 241 receptor, a novel G-protein coupled receptor |
| 06/12/2003 | US20030108906 Signal transduction, gene expression of pain sequences; genetic engineering |
| 06/12/2003 | US20030108650 Food ingredient enriched in vitamin E and phytosterol; useful as favoured food source meeting recommended daily intake |
| 06/12/2003 | US20030108624 Treating micro- and macroangiopathic conditions with a bioflavonoid plant extract as antioxidant along with a neovascular controller as an angiogenesis inhibitor; vision defects; wound healing agents; cardiovascular disorders |
| 06/12/2003 | US20030108623 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments |
| 06/12/2003 | US20030108622 Prophylactic or therapeutic treatment of soft tissue cancer, e.g. breast cancer; improving the effective treatment and reducing the adverse side effects of current anticancer therapy; antiproliferative, -carcinogenic agents |
| 06/12/2003 | US20030108621 Use of iodide salt as an aphrodisiac |
| 06/12/2003 | US20030108620 Prophylactic treatment of secondary injury of tissue traumatic event, surgery, transplant, nonproliferative tissue, burns, using of 3-methylsulfonyl-4-piperidinyl benzoyl)guanidine methanesulfonate or N,N-dimethylamiloride |
| 06/12/2003 | US20030108617 Use of a formulation made of or containing at least one dissimilated milk serum |
| 06/12/2003 | US20030108611 Bioactive particulates having a cationic surfactant adsorbed on their surfaces to provide superior adhesion to a biological substrate, e.g., an insect, teeth, bone, nails, chitin, feathers, plants, mucous, skin; drug delivery |
| 06/12/2003 | US20030108601 Liquid pharmaceutical for oral delivery |
| 06/12/2003 | US20030108575 Stabilized oral suspension formulation |
| 06/12/2003 | US20030108550 Anti-procalcitonin antibodies and the preparation and use thereof |
| 06/12/2003 | US20030108545 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 06/12/2003 | US20030108544 Compositions and methods for the diagnosis and treatment of tumor |
| 06/12/2003 | US20030108538 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| 06/12/2003 | US20030108518 TRX1 antibody and uses therefor |
| 06/12/2003 | US20030108496 Compositions comprising phenyl-glycine derivatives |
| 06/12/2003 | US20030107149 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| 06/12/2003 | CA2537913A1 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 06/12/2003 | CA2469356A1 Nuclear protein "shoca" - a component of the wnt signalling pathway |
| 06/12/2003 | CA2469228A1 Azole compound and medicinal use thereof |
| 06/12/2003 | CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 06/12/2003 | CA2469223A1 Trioxane derivatives as antimalaria or anticancer compounds |
| 06/12/2003 | CA2469130A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 06/12/2003 | CA2469104A1 Minor histocompatibility antigen ha-1: target antigen for immunotherapy of tumors |